Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Genmab A-SGMAB19.814.6920.29-0.2814.92%17.69%40.36$24.06$153.8645,606$20.66

Detail of Genmab A-S

 
CEO
Dr. Jan G.J. van de Winkel Ph.D.
Employees
2635
Industry
Biotechnology
Sector
Healthcare
Market cap
$93B

Company details

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Revenue
CoG
Gross profit
OE
R&D
G&A
OI
OIE
PI
TAX
NI
Revenue (Rev)
$19.76B
Cost of goods (CoG)
-$774.00M
Gross profit (GP)
$18.99B
Operating expense (OE)
-$12.58B
Research and development (R&D)
-$9.03B
General and administrative (G&A)
-$3.55B
Operating income (OI)
$6.41B
Other income expense (OIE)
-$912.00M
Pretax income (PI)
$6.49B
Tax (TAX)
-$1.85B
Net income (NI)
$4.64B
Genmab A-S
GMAB • XNGS • US
$20.66
-9.32 (-31.09%)
Stock vs Industry average
  • Industry average

Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
$1.04
Margin profit
23.70%
52 week low
$20.450001
52 week high
$31.68
50-day simple moving average
$0.00
200-day simple moving average
$24.06
Percent held by insiders
0.01%
Percent held by institutions
8.41%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Comparison of selected companies

 
%
Price change
GMAB -31.09%
eps change
GMAB -38.83%